Literature DB >> 6698909

Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro.

F C Odds, A B Abbott.   

Abstract

A system is described for measurement of relative inhibition factors (RIFs) for antifungal agents--that is, the area under a fixed portion of the antifungal dose-response curve, expressed as a percentage of the area under the dose-response curve for a theoretical noninhibitory substance. The RIFs for two polyenes, 5-fluorocytosine (5FC) and griseofulvin correlated with the known inhibitory activity of these compounds against pathogenic yeasts, Aspergillus spp. and dermatophytes in vitro and in vivo, but revealed wholly new relative inhibitory properties among five imidazole antifungals: ketoconazole and tioconazole emerged as the most active imidazole antifungals against yeasts and clotrimazole and econazole against Aspergillus spp. Because of the high reproducibility of the assay, and because tests were done in a tissue culture medium in the presence of serum, it is considered that measurement of RIFs could give better predictions of likely antifungal activity in vivo than is at present afforded by tests for minimal inhibitory concentrations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6698909     DOI: 10.1093/jac/13.1.31

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method.

Authors:  M T Blanco; C Pérez-Giraldo; J Blanco; F J Morán; C Hurtado; A C Gómez-García
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus.

Authors:  H C Korting; M Ollert; A Georgii; M Fröschl
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

Review 5.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 6.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

Authors:  M Haria; H M Bryson
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Effects of temperature on anti-Candida activities of antifungal antibiotics.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  New in vitro assay based on glucose consumption for determining intraconazole and amphotericin B activities against Aspergillus fumigatus.

Authors:  J C Garrigues; G Cadet de Fontenay; M D Linas; M Lagente; J P Seguela
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.

Authors:  R Guinet; D Nerson; F de Closets; J Dupouy-Camet; L Kures; M Marjollet; J L Poirot; A Ros; J Texier-Maugein; P J Volle
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.